<DOC>
	<DOCNO>NCT00196794</DOCNO>
	<brief_summary>Approximately 520 patient enter study take place throughout Australia Europe . This study aim determine investigational drug safe effective treating symptom C. difficile-associated diarrhea ( CDAD ) lower risk repeat episode CDAD . The investigational drug evaluate comparison current standard antibiotic treatment , patient receive active medication . All study relate care provide include doctor visit , physical exam , laboratory test , study medication . The total length participation approximately 6 week .</brief_summary>
	<brief_title>A Study GT267-004 Versus Vancomycin GT267-004 Versus Metronidazole Patients With C. Difficile-Associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Enterocolitis</mesh_term>
	<mesh_term>Enterocolitis , Pseudomembranous</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>18 year age The presence CDAD time enrollment likely etiology diarrhea Less equal 48 hour treatment metronidazole , vancomycin antibacterial therapy specific CDAD Baseline serum potassium &gt; 3.0 mmol ( meq ) /L Patient consider sufficiently stable clinically likely complete 6 week study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pseudomembranous Colitis</keyword>
	<keyword>Clostridium difficile-associated diarrhea</keyword>
	<keyword>C. difficile</keyword>
	<keyword>CDAD</keyword>
</DOC>